<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38797">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601313</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-102</org_study_id>
    <nct_id>NCT02601313</nct_id>
  </id_info>
  <brief_title>A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
  <acronym>ZUMA-2</acronym>
  <official_title>A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of
      KTE-C19 in subjects with Relapsed/Refractory MCL
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 2: Overall Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>• Objective response rate (complete response [CR] + partial response [PR]) per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Objective Response</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Relapsed/Refractory Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>KTE-C19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Single Arm A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KTE-C19</intervention_name>
    <arm_group_label>KTE-C19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Pathologically confirmed MCL

          -  Up to 5 prior regimens for MCL. Prior therapy must have included:

               -  Anthracycline or bendamustine-containing chemotherapy and

               -  Anti-CD20 monoclonal antibody therapy and

               -  Ibrutinib

          -  Relapsed or refractory disease, defined by the following:

               -  Disease progression after last regimen, or

               -  Refractory disease is defined failure to achieve a PR or CR to the last regimen

          -  At least 1 measurable lesion according to the revised IWG Response Criteria for
             Malignant Lymphoma

          -  Age 18 years or older

          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1

          -  ANC ≥ 1000/µL

          -  Platelet count ≥ 50,000/µL

          -  Adequate renal, hepatic, and cardiac function defined as:

               -  Serum creatinine ≤ 1.5 mg/dL

               -  Serum ALT/AST ≤ 2.5 ULN

               -  Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's syndrome.

               -  Cardiac ejection fraction ≥ 50% (by ECHO) and no evidence of pericardial
                  effusion as determined by an ECHO.

        Key Exclusion Criteria:

          -  History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ
             (e.g. cervix, bladder, breast) unless disease free for at least 3 years

          -  History of allogeneic stem cell transplantation

          -  Prior CD19 targeted therapy

          -  Prior CAR therapy or other genetically modified T cell therapy

          -  Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C
             virus (anti-HCV positive)

          -  Subjects with detectable cerebrospinal fluid malignant cells or brain metastases or
             with a history of cerebrospinal fluid malignant cells or brain metastases

          -  History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,
             cerebellar disease, or any autoimmune disease with CNS involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Go, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kite Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Bowen, MPM, PMP, BS, BA</last_name>
    <email>Allison.Bowen@Chiltern.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Horstman</last_name>
      <email>andrea.horstman@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarmad Bahrani</last_name>
      <email>sbahrani@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Le</last_name>
      <email>ryanle@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juli Murphy</last_name>
      <email>juli.murphy@healthonecares.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Bresee</last_name>
      <email>Bethany.Bresee@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neera Jagirdar</last_name>
      <email>neera.jagirdar@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Schroeder</last_name>
      <email>lschroed@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rocchio</last_name>
      <email>MichaelJ_Rocchio@DFCI.HARVARD.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Ventimiglia</last_name>
      <email>ventimim@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Marrero</last_name>
      <email>william.marrero@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Baloga</last_name>
      <email>elizabeth_baloga@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Abounader</last_name>
      <email>abounad2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert W. Franz Cancer Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Delanty</last_name>
      <email>laurie.delanty@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Cardona</last_name>
      <email>tiffany.cardona@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Li</last_name>
      <email>Sandy.Li@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Badillo</last_name>
      <email>mrbadill@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Onyeka Oriabure</last_name>
      <email>ONOkonkwo@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoDell McCracken</last_name>
      <email>jodell.mccracken@mhshealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>November 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
